Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer

Cancer Investigation

Volumn 19, Issue 1, 2001, Pages 1-7

  Safran, H ^a   Gaissert, H ^a   Akerman, P ^a   Hesketh, P J ^a   Chen, M H ^a   Moore, T ^a   Koness, J ^a   Graziano, S ^a   Wanebo, H J ^a  

^a MIRIAM HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ENTERIC FEEDING; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HUMAN; IRRADIATION; LYMPHADENOPATHY; MALE; METASTASIS; NEUTROPENIA; PARENTERAL NUTRITION; PERITONITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION DOSE; RADIOSENSITIZATION; SEPSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; SURVIVAL RATE;

EID: 0035078336     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-100000068     Document Type: Article

References (33)

1. The increasing frequency of adenocarcinoma of the esophagus
2. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
3. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma
4. A randomized trial comparing surgery (S) to preoperative concomitant chemoradiation plus surgery in patients (Pts) with resectable esophageal cancer
5. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus
6. Investigation of taxol as a potential radiation sensitizer
7. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells
8. In vitro studies of taxol as a radiation sensitizer in human tumor cells
9. Taxol in combination with acute and low dose rate irradiation
10. Multi-institutional phase II trial of paclitaxel. Carboplatin and concurrent radiation therapy for locally advanced non-small cell lung cancer
11. A phase I trial of concurrent weekly taxol administered as a 3 hour infusion and radiation therapy for advanced non-small cell lung cancer
12. Phase II study of paclitaxel and cisplatin in patients with advanced adenocarcinoma (A) and squamous cell (S) carcinoma of the esophagus
13. Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation
14. Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction
15. p53 Status and the efficacy of cancer therapy in vivo
16. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents
17. The cell cycle. Probing new molecular determinants of resistance and sensitivity to cytotoxic agents
18. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with the growth-inhibitory potency of 123 anticancer agents
19. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis
20. p53 Mutations do not predict response to paclitaxel/radiation for non-small cell lung cancer
21. Effect of paclitaxel (Taxol) alone and in combination with radiation of the gastrointestinal mucosa
22. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas
23. Preoperative paclitaxel, carboplatin and radiation in advanced head and neck cancer (Stage III and IV) induces a high rate of complete pathologic response (CR) at the primary site and high rate of organ preservation
24. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma
25. Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus
26. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus
27. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: Final report
28. A phase I/II of preoperative taxol (T), cisplatin (P), 5-FU (F) and concurrent boost radiation (XRT) in esophageal cancer
29. Preoperative therapy with paclitaxel, carboplatin, 5-FU and radiation in the treatment of local esophageal cancer
30. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: Results and commentary
31. Phase I/II neoadjuvant concurrent 96 hour taxol, cisplatin, and radiation therapy: Promising toxicity profile and response in localized esophageal cancer
32. A phase I trial of radiation therapy (Rt) plus concurrent fixed dose cisplatin (C) with escalating doses of paclitaxel (P) as a 96 hour continuous infusion in patients (Pts) with localized esophageal cancer (EC)
33. Novel approaches in development for the treatment of pancreatic cancer